Primary angiosarcoma Whole Genome Sequencing
Ontology highlight
ABSTRACT:
PROVIDER: EGAS00001000851 | EGA |
REPOSITORIES: EGA
Similar Datasets
Project description:Analysis of the effects of 4 hr and 24 hr propranolol treatment on gene expression of SVR mouse angiosarcoma cells. The hypothesis tested in the present study was that inhibiton of beta adrenergic receptor signaling could ablate the oncogenic properties of angiosarcoma cells. Results provide important information of the response of angiosarcoma cells to ablated beta adrenergic receptor signaling. The total RNA was obtained from mouse angiosarcoma cells cultured in monolayer at 0, 4, and 24 hrs of 50 micromolar propranolol treatment. Illumina microarrays were performed to determine the whole genome expression changes following treatment.
2013-06-01 | E-GEOD-42534 | biostudies-arrayexpress
Project description:Angiosarcomas are ultra-rare, highly aggressive sarcomas with limited treatment options and dismal prognosis. In this project, we quantified immune cell infiltrates in the angiosarcoma tumor microenvironment. Unsupervised clustering was applied to reveal prognostically significant immune phenotypes. Proteomic profiling of 88 angiosarcoma samples (54 primary tissue, 17 local relapse tissue, and 17 metastatic tissue), 20 benign control tissues and 9 pooled groups was performed by LC–MS/MS to compare various AS subtypes, as well as up- and downregulated pathways between immune cell clusters.
2026-03-13 | PXD070528 | Pride
Project description:Whole Exome sequencing of two patients with Cardiac angiosarcoma in Li-Fraumeni-like families discovers that a mutation in the pot1 gene is responsible for cardiac angiosarcoma in tp53-negative li-fraumeni-like families
2015-09-14 | E-MTAB-3858 | biostudies-arrayexpress
Project description:Extension of angiosarcoma whole genome sequencing study
| EGAS00001000588 | EGA
Project description:Analysis of the effects of 4 hr and 24 hr propranolol treatment on gene expression of SVR mouse angiosarcoma cells. The hypothesis tested in the present study was that inhibiton of beta adrenergic receptor signaling could ablate the oncogenic properties of angiosarcoma cells. Results provide important information of the response of angiosarcoma cells to ablated beta adrenergic receptor signaling.
2013-06-01 | GSE42534 | GEO
Project description:This study investigates multidrug-resistant Klebsiella pneumoniae KP21-10C using whole genome sequencing and targeted energy metabolomics. Genomic sequencing data were generated to characterize the bacterial genome, and targeted LC-MS/MS metabolomics was performed to quantify energy metabolism-related metabolites under doxycycline monotherapy and cepharanthine hydrochloride plus doxycycline combination treatment.
2026-06-25 | MTBLS14858 | MetaboLights
Project description:Extension of angiosarcoma whole genome sequencing study
| EGAS00001000590 | EGA
Project description:A comparison of gene expression in OCT frozen human angiosarcoma compared with OCT frozen normal mesenchymal tissues
2013-10-21 | GSE44115 | GEO
Project description:Angiosarcoma is an aggressive soft-tissue sarcoma with a poor prognosis. Chemotherapy for this cancer typically employs paclitaxel, one of the taxanes (genotoxic drugs), although it has a limited effect due to chemoresistance for prolonged treatment. Here we examine a new angiosarcoma treatment approach that combines chemotherapeutic and senolytic agents. We first find that the chemotherapeutic drugs, cisplatin and paclitaxel, efficiently induce cellular senescence of angiosarcoma cells. Subsequent treatment with a senolytic agent, ABT-263, eliminates senescent cells through the activation of the apoptotic pathway. In addition, expression analysis indicates that senescence-associated secretory phenotype (SASP) genes are activated in senescent angiosarcoma cells and that ABT-263 treatment eliminates senescent cells expressing genes in the type-I interferon (IFN-I) pathway. Moreover, we show that cisplatin treatment alone requires a high dose to remove angiosarcoma cells, whereas a lower dose of cisplatin is sufficient to induce senescence, followed by the elimination of senescent cells by senolytic treatment. This study sheds light on a potential therapeutic strategy against angiosarcoma by combining a relatively low dose of cisplatin with the ABT-263 senolytic agent, which can help ease the deleterious side effects of chemotherapy.
2024-03-23 | GSE245935 | GEO
Project description:Angiosarcomas are highly malignant tumors that develop as primary angiosarcomas of unknown cause or as secondary angiosarcomas, most often following radiation therapy for breast cancer. These subsets are morphologically indistinguishable, which motivates our aim to identify genetic classifiers for diagnostic and therapeutic application. We applied the 18k whole-genome c-DNA-mediated annealing, selection, extension, and ligation (WG-DASL) assay for expression profiling of 26 primary and 29 secondary angiosarcomas. Primary and secondary angiosarcomas differed by 103 significantly de-regulated genes with up-regulation of RET, KIT, FLT4, MYC and RASGRP3 and down-regulation of CDKN2C in secondary angiosarcoma. Functional annotation analysis demonstrated involvement of multiple target genes in the receptor protein tyrosine kinase pathway. Up-regulation of RET and down-regulation of CDKN2C characterize secondary angiosarcoma, which implies a mechanistic basis for the evaluation of RET-kinase inhibitors in the treatment of these highly aggressive tumors.
2014-08-22 | GSE52664 | GEO